Tryton Announces Events at European Bifurcation Club Meeting

DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to
definitively treat bifurcation lesions, today announced that the
company’s TRYTON Side Branch Stent™ System will be featured in
discussions by a number of leading cardiologists in a symposium on Oct.
16, 2009, in conjunction with the European Bifurcation Club meeting in
Berlin, Germany.

Symposium presenters who will discuss the Tryton solution include
Antonio Bartorelli, M.D., director of Interventional Cardiology, CCM,
and Professor of Cardiology, University of Milan; Maciej Lesiak M.D.,
Ph.D. Department of Cardiology, University Hospital in Poznan; and
Patrick W. Serruys, M.D., Ph.D., of Erasmus Medical Center in Rotterdam,
the Netherlands.

“This is an exciting time for Tryton. Hundreds of patients with
difficult-to-treat cases have now been helped by physicians utilizing
our device, and our solution for bifurcation lesions is gaining the
attention of some of the world’s most renowned cardiologists,” said J.
Greg Davis, president and CEO of Tryton Medical. “We look forward to
participating in the annual European Bifurcation Club meeting this week,
which serves as an ideal forum for clinicians to share best practices
for treating bifurcation lesions.”

Tryton Medical at the European Bifurcation Club Meeting 2009

Also on Oct. 16, Dr. Bartorelli will present during the European
Bifurcation Club meeting his experience using the Tryton stent system.
As part of that presentation he will provide an update on results of a
study analyzing acute and long-term results of the Tryton Side Branch
Stent used in conjunction with Abbott’s XIENCE V® Everolimus Eluting
Coronary Stent System.

About the Tryton Side Branch Stent System

The Tryton Side Branch Stent System is designed to offer a dedicated
strategy for treating atherosclerotic lesions in the side branch at the
site of a bifurcation. These areas of the vascular system are a common
location for plaque and are particularly challenging to treat with
currently available stent systems. Approximately twenty percent of
patients treated for coronary artery disease have diseased bifurcated
lesions.

Tryton’s highly deliverable cobalt chromium stent is deployed in the
side branch artery using a standard single-wire balloon-expandable stent
delivery system. A conventional drug-eluting stent is then placed in the
main vessel.

The Tryton Side Branch Stent System demonstrated excellent six-month
clinical results in a first-in-man study of the system in 30 patients,
with no restenosis occurring in the side branch artery. The stent system
has received CE Mark approval in Europe and is not approved in the
United States.

About Tryton Medical, Inc.

Tryton Medical, Inc., located in Durham, N.C., is a leading developer of
novel stent systems for the treatment of bifurcation lesions. The
company`s Side Branch Stent System, approved for sale in Europe, is
designed to offer a dedicated strategy for treating these challenging
cases. The privately held company is backed by Spray Ventures, PTV
Sciences, and RiverVest Ventures. For more information please visit trytonmedical.com.